Corient Private Wealth LLC Takes $320,000 Position in Xeris Biopharma Holdings, Inc. $XERS

Corient Private Wealth LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 68,500 shares of the company’s stock, valued at approximately $320,000.

Several other hedge funds have also added to or reduced their stakes in the company. Qube Research & Technologies Ltd boosted its stake in Xeris Biopharma by 67.5% in the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock valued at $14,429,000 after acquiring an additional 1,245,188 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in Xeris Biopharma by 207.8% during the first quarter. Parkman Healthcare Partners LLC now owns 1,780,454 shares of the company’s stock valued at $9,775,000 after purchasing an additional 1,201,943 shares during the period. Goldman Sachs Group Inc. increased its stake in Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. CenterBook Partners LP raised its holdings in Xeris Biopharma by 237.7% in the second quarter. CenterBook Partners LP now owns 1,594,229 shares of the company’s stock worth $7,445,000 after purchasing an additional 1,122,154 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Xeris Biopharma during the first quarter worth $4,456,000. Institutional investors own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on XERS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th. Oppenheimer restated an “outperform” rating and issued a $18.00 price target on shares of Xeris Biopharma in a report on Friday, November 7th. Piper Sandler lifted their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research report on Friday, November 7th. Finally, Zacks Research downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 30th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

Insider Buying and Selling

In related news, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $7.01, for a total value of $116,835.67. Following the completion of the transaction, the insider directly owned 1,320,176 shares of the company’s stock, valued at approximately $9,254,433.76. This trade represents a 1.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Johnson sold 135,400 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.22, for a total transaction of $977,588.00. Following the transaction, the director owned 698,083 shares in the company, valued at approximately $5,040,159.26. The trade was a 16.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 206,976 shares of company stock worth $1,497,495 over the last 90 days. Company insiders own 4.56% of the company’s stock.

Xeris Biopharma Trading Down 1.6%

Xeris Biopharma stock opened at $7.31 on Wednesday. Xeris Biopharma Holdings, Inc. has a 1-year low of $3.14 and a 1-year high of $10.08. The company has a fifty day simple moving average of $7.66 and a 200 day simple moving average of $7.03. The company has a market cap of $1.21 billion, a P/E ratio of -73.09 and a beta of 0.58.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.01). The firm had revenue of $74.38 million during the quarter, compared to the consensus estimate of $74.19 million. On average, equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.